Antigen-specific immune responses  through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC).

Authors

Emmanuel S. Antonarakis

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Emmanuel S. Antonarakis , Adam S. Kibel , George W. Adams , Lawrence Ivan Karsh , Aymen Elfiky , Neal D. Shore , Nicholas J. Vogelzang , John M. Corman , Robert Claude Tyler , Candice McCoy , Todd DeVries , Nadeem A. Sheikh , Charles G. Drake

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure.

First Author: Emmanuel S. Antonarakis

insert_chart_outlined

Poster

2013 Genitourinary Cancers Symposium

bookmark_border

Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).

First Author: Emmanuel S. Antonarakis

insert_chart_outlined

Poster

2020 Genitourinary Cancers Symposium

bookmark_border

Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa).

First Author: Hamid Emamekhoo

insert_chart_outlined

Poster

2017 Genitourinary Cancers Symposium

bookmark_border

Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).

First Author: Lawrence Fong